Roswitha Verwer and Dr. Muskaan Bhan share their journey from preclinical validation through regulatory approval, currently at TRL4, pursuing CE Mark and FDA De Novo. The conversation offers insights into how real-time biomarker data can transform women’s reproductive health while overcoming investor skepticism, taboo, and market barriers when solving decades-old clinical blind spots in women’s health.

“Roswitha Verwer en YON E Health bouwen aan een nieuwe generatie FemTech-innovatie door real-time data over vaginale gezondheid toegankelijk te maken voor vrouwen.”

“YON E Health raises €250k pre-Seed to advance a first-of-its-kind smart vaginal health device measuring pH and temperature for fertility, infection risk, and reproductive wellbeing, strengthening Europe’s growing FemTech market with science-backed, women-centered innovation.”

“Roswitha Verwer, CEO of YON E Health, is building data-driven solutions to transform women’s health. Driven by lived experience, she is breaking taboos in vaginal health and fertility, turning real-time biomarker insights into personalized care for women worldwide.”

“Roswitha Verwer, CEO of YON E Health, is pioneering data-driven innovation in women’s health. She leads the development of a smart vaginal health device, transforming taboo topics into real-time insights for fertility, prevention, and personalized care.”